GLP-1 Drug Safety Review Finds Suicidality Reports but No Proven Causal Link — Lower Rates Than Metformin

This pharmacovigilance study analyzed adverse drug reports from the FDA Adverse Events Reporting System (FAERS) from 2005 to 2023. Descriptive and disproportionality analyses were performed using reported odds ratios. An unmasking analysis was conducted to identify individual drug contributions. GLP-1 RAs were compared against metformin and orlistat as reference drugs. Selected preferred terms related to suicidal ideation, self-injury, and suicide were analyzed.

With GLP-1 drugs being prescribed to tens of millions of people for weight loss and diabetes, even rare psychiatric side effects could affect many patients. This comprehensive FAERS analysis provides the most detailed drug-by-drug breakdown of suicidality reports across GLP-1 agonists published to date. The finding that metformin actually has higher psychiatric reporting rates provides important context and suggests these signals may reflect underlying disease risk rather than drug effects.

The psychiatric safety of GLP-1 drugs is one of the most closely watched pharmacovigilance topics in medicine. This study adds nuance to the debate: while suicidality signals exist for some GLP-1 drugs, they're lower than for metformin — a drug that's been used safely for decades without major psychiatric safety concerns. The authors hypothesize that rapid weight loss itself may trigger emotional and psychological responses, suggesting the issue may not be the drugs per se but the physiological changes they induce.

FAERS is a spontaneous reporting system with inherent biases including underreporting, reporting bias (more attention to GLP-1 psychiatric effects increases reporting), and the inability to establish causation. Patients taking these drugs often have comorbid conditions (depression, diabetes) that independently increase suicide risk. The comparison with metformin is informative but both populations differ in many ways. Denominator data (total prescriptions) is not available in FAERS, preventing incidence rate calculations.